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Abstract We have previously shown that exogenous calmodu-
lin (CaM) binds to the epidermal growth factor receptor
(EGFR) at its cytosolic juxtamembrane region inhibiting its
tyrosine kinase activity. We demonstrate in this report that
endogenous CaM binds to EGFR in intact cells as CaM co-
immunoprecipitates with EGF-activated and non-activated re-
ceptors. We also show in living cells that cell-permeable CaM
inhibitors prevent the full transphosphorylation of wild type
EGFR but not the transphosphorylation of an insertional
EGFR mutant in which the CaM-binding domain was divided
into two parts. Overall these results suggest that CaM interacts
with EGFR in vivo.
& 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
An early signal generated by the activation of epidermal
growth factor receptor (EGFR) upon ligand binding is a tran-
sient increase in the cytosolic concentration of free calcium
ion ([Ca2þ]cyt) (see for review [1]). Entry of extracellular Ca2þ,
and Ca2þ release from intracellular stores, both appear to
contribute to the generation of the EGF-mediated [Ca2þ]cyt
spike [2^4]. Despite being a short-lived event, this process
has great importance for the functioning of the receptor, as
it is relevant for the inhibition of its tyrosine kinase activity,
abating in this manner subsequent downstream signaling. In
addition to promoting the activation of protein kinase C,
which phosphorylates Thr654 at the EGFR inducing its
downregulation [5^8], this Ca2þ surge facilitates the formation
of the Ca2þ/calmodulin (CaM) complex [9]. This complex in
turn activates calmodulin-dependent protein kinase II
(CaMK-II) further phosphorylating Ser1046/Ser1047 at the
EGFR, contributing in this manner to the inhibition of the
receptor tyrosine kinase activity [10,11].
In addition to the indirect regulation of EGFR by the Ca2þ/
CaM complex because of the activation of CaMK-II, our
group has shown that CaM directly binds to this receptor at
its cytosolic juxtamembrane region (Arg645^Gln660) in a
Ca2þ-dependent manner, inducing the inhibition of its tyro-
sine kinase activity [12^16]. The interaction of the Ca2þ/CaM
complex at the cytosolic juxtamembrane region of the recep-
tor has been con¢rmed by others [17]. Likewise, we have
demonstrated that the Ca2þ-dependent binding of CaM to
this EGFR segment prevents the phosphorylation of Thr654
by protein kinase C, and conversely the phosphorylation of
this residue prevents CaM binding [14].
Despite these accumulated observations, no evidence was
available until now on the direct interaction of endogenous
CaM with EGFR, although CaM has being implicated in the
regulation of the intracellular sorting and tra⁄cking of the
receptor in intact cells [18]. In this report we ¢ll this gap by
showing that endogenous CaM can be co-immunoprecipitated
with EGFR from two di¡erent cell lines overexpressing this
receptor, and that cell-permeable CaM antagonists partially
inhibit the EGF-dependent transphosphorylation of wild type
EGFR but not the transphosphorylation of an EGFR mutant
in which its CaM-binding domain was split into two parts by
the insertion of a non-relevant sequence. This suggests that a
CaM/EGFR complex is present in living cells, and that the
described CaM-binding domain [12,14,15,17] has indeed a
functional role in vivo.
2. Materials and methods
2.1. Reagents
Monoclonal anti-CaM antibody developed in mouse (recognizing
the carboxy-terminal amino acids 128^148 of human CaM) was ob-
tained from Upstate Biotechnology. Monoclonal anti-EGFR antibod-
ies (clone 13 recognizing the intracellular segment 996^1022, and clone
528 recognizing the extracellular domain of the human receptor) de-
veloped in mouse, and mouse monoclonal anti-phosphotyrosine RC20
antibody conjugated to horseradish peroxidase were obtained from
Transduction Laboratories. Anti-mouse immunoglobulin G (IgG)
(Fc-speci¢c) developed in goat and conjugated to horseradish peroxi-
dase, deoxycholic acid (sodium salt), Triton X-100, Tween 20, Fast
green FCF, bicinchoninic acid, copper sulfate, sodium orthovanadate,
leupeptin, pepstatin A, aprotinin, and phenylmethylsulfonyl £uoride
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(PMSF) were purchased from Sigma. Human recombinant EGF was
obtained from PeproTech EC, and the prestained molecular mass
standards for electrophoresis were from Bio-Rad. N-(6-Aminohex-
yl)-5-chloro-1-naphthalenesulfonamide (W7), N-(4-aminobutyl)-1-
naphthalenesulfonamide (W12), and N-(4-aminobutyl)-5-chloro-1-
naphthalenesulfonamide (W13) were from Calbiochem, and Bio-
Trace1 polyvinylidene di£uoride (PVDF) membranes were purchased
from Pall Gelman Laboratory. The enhanced chemiluminescence Lu-
minol (ECL1) reagents were from Amersham Pharmacia Biotech.
Other chemicals used in this work were of analytical grade.
2.2. Cell cultures
Murine EGFR-T17 ¢broblasts, a stably transfected cell line over-
expressing the human EGFR [19] (donated by Dr. J.M. Mato, Insti-
tuto de Investigaciones Biome¤dicas, Madrid, Spain), human epider-
moid carcinoma A431 cells overexpressing EGFR [20] (donated by
Dr. R. Perona, Instituto de Investigaciones Biome¤dicas, Madrid,
Spain), RI1 ¢broblasts, a stably transfected cell line expressing a hu-
man EGFR mutant with the insertion of a non-relevant highly acidic
23 amino acid sequence between Arg647 and His648 dividing into two
segments the CaM-binding domain [21] (donated by Dr. A. Sorokin,
Medical College of Wisconsin, Milwaukee, WI, USA), and N7xHERc
¢broblasts, a stably transfected cell line expressing the wild type hu-
man EGFR (donated by Dr. A. Ullrich, Max-Planck-Institut fu«r Bio-
chemie, Martinsried, Germany), were grown in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% (v/v) fetal bovine serum
(FBS), 2 mM L-glutamine and 40 Wg/ml gentamicin in a humidi¢ed
atmosphere of 5% (v/v) CO2 in air at 37‡C. The cells were maintained
overnight in an FBS-free medium before performing the experiments.
2.3. Co-immunoprecipitation of CaM with EGFR
Serum-starved con£uent A431 tumor cells and EGFR-T17 ¢bro-
blasts grown in 10 dishes of 15 cm diameter containing 10 ml of
culture medium were incubated in duplicate for 1 min at room tem-
perature in the absence and presence of 10 nM EGF or at the con-
centrations indicated in the legends of the ¢gures. Thereafter, the
medium was removed and 1 ml of a lysis bu¡er containing 50 mM
Tris^HCl (pH 8), 150 mM NaCl, 1 mM [ethylene bis(oxyethyleneni-
trilo)]-tetraacetic acid (EGTA), 0.3% (w/v) Triton X-100, 0.16% de-
oxycholic acid, 1 mM sodium orthovanadate, 1 mM PMSF, 10 Wg/ml
leupeptin, 10 Wg/ml pepstatin A, and 10 Wg/ml aprotinin was added
and incubated for 30 min on ice. The cell extract was collected by
centrifugation on a bench-top centrifuge at 15 600Ugmax for 35 min,
and 1.5 mM CaCl2 was added to the supernatant. Solubilized proteins
(2^5.2 mg) were incubated for 3^12 h in 200 Wl of a medium contain-
ing 50 mM Tris^HCl (pH 8), 150 mM NaCl, 1 mM EGTA, 1.5 mM
CaCl2 (0.5 mM free Ca2þ), 1 mM sodium orthovanadate, 1 mM
PMSF, and 1.5 Wg anti-EGFR antibody (recognizing the extracellular
domain) precoupled to 30 Wl slurry of protein A-agarose. The beads
were collected by low-speed centrifugation and washed six times in a
bu¡er containing 50 mM Tris^HCl (pH 8), 150 mM NaCl, 1 mM
sodium orthovanadate, and 1 mM PMSF. Mock immunoprecipitation
experiments were performed using 1.5 Wg of a non-relevant mouse
IgG fraction. The samples were boiled for 5 min in Laemmli sample
bu¡er, the beads were removed by low-speed centrifugation, and the
supernatant processed by polyacrylamide gel electrophoresis in the
presence of sodium dodecyl sulfate (SDS^PAGE) and Western blot
analysis as described below.
2.4. CaM antagonist treatment and activation of EGFR in living cells
Cells grown to con£uence in 6 well culture dishes containing 2 ml of
culture medium, and deprived of FBS overnight, were incubated for
15 min at room temperature with the CaM antagonists W7, W12 or
W13 at the concentrations indicated in the ¢gures. Thereafter, 10 nM
EGF was added and the incubation was continued for di¡erent peri-
ods of time (30 s to 30 min) as indicated in the ¢gures, and the
reaction was arrested upon addition of 10% (w/v) trichloroacetic
acid. The precipitated proteins were boiled for 5 min in Laemmli
sample bu¡er. The tyrosine phosphorylation level of EGFR was de-
termined after SDS^PAGE and Western blot analysis using an anti-
phosphotyrosine antibody as described below.
2.5. Electrophoresis and immunoblot analysis
Slab gel electrophoresis was performed according to Laemmli [22]
at 12 mA overnight in a linear gradient 5^20% (w/v) polyacrylamide
gel in the presence of 0.1% (w/v) SDS at pH 8.3. Proteins in the gel
were electrotransferred to a PVDF membrane in a medium containing
48 mM Tris base, 36.6 mM glycine, 0.04% (w/v) SDS, and 20% (v/v)
methanol, and the proteins were ¢xed with 0.2% (v/v) glutaraldehyde
for 45 min in a medium containing 0.1% (w/v) Tween 20, 100 mM
Tris^HCl (pH 8.8), 0.5 M NaCl, and 0.25 mM KCl (T-TBS medium).
The PVDF membrane was blocked with 5% (w/v) bovine serum al-
bumin in T-TBS medium and probed with the anti-phosphotyrosine
antibody conjugated to horseradish peroxidase (1/2000 dilution). The
upper part of the PVDF membrane was stripped in a medium con-
taining 100 mM L-mercaptoethanol, 2% (w/v) SDS and 62.5 mM
Tris^HCl (pH 6.7) at 50‡C for 30 min, or after overnight incubation
at room temperature, and reprobed with the anti-EGFR antibody
recognizing the intracellular domain (1/2500 dilution). The lower
part of the PVDF membrane was probed with the anti-CaM antibody
(1/1000 dilution). Anti-mouse IgG coupled to horseradish peroxidase
(1/3000 dilution) was used as secondary antibody in both instances.
The positive bands were developed, after appropriate time exposure,
using the ECL1 method following instructions from the manufac-
turer. When required, the intensity of the phosphotyrosine-containing
EGFR band was quanti¢ed with a computer-assisted scanning densi-
tometer using the NIH Image 1.59 program. Corrections were made
for the amount of protein present in the electrophoretic tracks as
detected by Fast green FCF staining after densitometric reading.
2.6. Protein determination
The protein concentration was determined using bicinchoninic acid
and copper sulfate (BCA method) using standards of bovine serum
albumin as described [23].
3. Results
3.1. CaM co-immunoprecipitates with EGFR
To test whether endogenous CaM directly interacts with
EGFR, we prepared solubilized whole cell extracts from
non-stimulated EGFR-T17 ¢broblasts and A431 tumor cells,
and performed immunoprecipitation experiments in the pres-
Fig. 1. Endogenous CaM co-immunoprecipitates with EGFR. Solu-
bilized whole cell extracts from EGFR-T17 ¢broblasts (3 mg pro-
tein) and A431 tumor cells (5.2 mg protein) were subjected to im-
munoprecipitation (IP) using an anti-EGFR antibody (K-EGFR).
Mock immunoprecipitation experiments using a non-relevant mouse
IgG fraction instead of the anti-EGFR are also presented. The sam-
ples were separated by SDS^PAGE, electrotransferred to a PVDF
membrane, and the upper and lower parts of this membrane were
probed, respectively, with anti-EGFR (K-EGFR), and anti-CaM (K-
CaM) antibodies by Western blot analysis (WB). Loading controls
showing the amount of IgG present in the samples as detected using
the secondary anti-mouse IgG antibody (K-IgG) coupled to peroxi-
dase are also presented. The apparent molecular masses of the dif-
ferent bands were as follows: EGFR 170 kDa, CaM 21 kDa (be-
cause EGTA present), and IgG 55 kDa. Representative experiments
of seven performed in EGFR-T17 ¢broblasts and six performed in
A431 tumor cells are presented.
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ence of Ca2þ using an anti-EGFR antibody (K-EGFR). Fig. 1
shows that the immunoprecipitated material from both cell
lines gave a positive signal when probed with an anti-CaM
antibody (K-CaM) using Western blot analysis. A faint CaM
signal was detected in the material derived from mock immu-
noprecipitations using a non-relevant mouse IgG fraction in-
stead of the anti-EGFR antibody. This latter spurious signal,
which does not interfere with our results, could be the con-
sequence of non-speci¢c binding of trace amounts of CaM to
the protein A-agarose beads used to pull down the immune
complex, and it was more noticeable in A431 tumor cells than
in EGFR-T17 ¢broblasts. As expected, controls reveal that
EGFR was present in the immunoprecipitated material but
not in mock samples when probed using an anti-EGFR anti-
body (K-EGFR). To ascertain that comparable amounts of
sample were analyzed in each lane, we show the IgG signal
detected in the immune complexes using the secondary anti-
IgG antibody (K-IgG) coupled to peroxidase.
Our previous results demonstrated that the interaction of
exogenous CaM with EGFR was not signi¢cantly a¡ected by
the degree of tyrosine phosphorylation of the receptor [16]. To
determine if this is also the case for the interaction of endog-
enous CaM with EGFR, we performed co-immunoprecipita-
tion experiments using EGFR-T17 and A431 cells that were
previously exposed to increasing concentrations of EGF for
1 min in order to transphosphorylate the receptor at its max-
imum level.
The results in Fig. 2 clearly show that increasing concen-
trations of EGF up to 50 nM progressively increase the tyro-
sine phosphorylation of the immunoprecipitated EGFR from
EGFR-T17 ¢broblasts as determined by Western blot using
an anti-phosphotyrosine antibody (K-P-Tyr). In contrast, the
phosphorylation level of the immunoprecipitated receptor
from A431 tumor cells was already high in the absence of
EGF, and little increase was observed when cells were stimu-
lated with 50 nM EGF. Reprobing the stripped PVDF mem-
brane with an anti-EGFR antibody (K-EGFR) shows that
comparable amounts of receptor were present in the di¡erent
samples, except in mock immunoprecipitation experiments us-
ing a non-relevant mouse IgG fraction instead of the anti-
EGFR antibody. In all cases, however, we show that the
signal corresponding to CaM as probed with an anti-CaM
antibody (K-CaM) was invariant. This demonstrates that the
degree of activation of the EGFR, as inferred from its tyro-
sine phosphorylation status, does not signi¢cantly modify the
extent of binding of endogenous CaM to the receptor, in
agreement with our previous results using exogenous CaM
[16]. We again con¢rm in Fig. 2 that little, if any, CaM signal
was detected in mock immunoprecipitation experiments. As
previously indicated, the IgG signal detected in the immune
complexes using the secondary anti-IgG antibody (K-IgG)
coupled to peroxidase is also shown to ascertain that a similar
amount of samples were present in each lane.
3.2. Cell-permeable CaM antagonists prevent full EGFR
activation in intact cells
To obtain information about the possible functional role of
endogenous CaM on EGFR, we incubated intact cells with a
set of structurally related cell-permeable CaM antagonists but
with increasing a⁄nities for this Ca2þ regulator
(W12IW136W7), and determined the degree of EGF-in-
duced transphosphorylation of the receptor after treatment
with these compounds. We performed these experiments in
N7xHERc ¢broblasts, a transfected cell line expressing the
human EGFR in lesser extent than EGFR-T17 ¢broblasts.
Fig. 3A shows that increasing concentrations of W7 and
W13 signi¢cantly prevented the full transphosphorylation of
EGFR, reaching a CaM antagonist-resistant plateau (approx-
imately 50^60% inhibition) at approximately 40 WM, while
W12 had a far lesser inhibitory e¡ect. Moreover, the degree
of inhibition of EGFR transphosphorylation inversely corre-
lates with the average inhibition constant (IC50) of these com-
pounds for CaM expressed in a logarithmic scale (see Fig.
3B), suggesting that this e¡ect was indeed due to the inhibi-
tion of endogenous CaM. Moreover, we have calculated that
the average IC50s for EGFR transphosphorylation were 12
WM for W7, 33 WM for W13, and s 100 WM for W12, well
within the range described for other systems. We have previ-
ously determined that W7, W13, and W12 do not have any
inhibitory action on the tyrosine kinase activity of a puri¢ed
EGFR preparation (Ruano, Salas and Villalobo, unpublished
results), further suggesting that the observed e¡ect in intact
cells was due to endogenous CaM inactivation.
3.3. An insertional EGFR mutant at its CaM-binding domain is
resistant to CaM antagonist action
To determine whether the described CaM-binding domain
of EGFR, comprising Arg645^Gln660 [12,14,15,17], partici-
pates in the regulation of EGFR transphosphorylation in liv-
ing cells, we performed the following experiments. We studied
the e¡ect of W13 on the activation of both wild type EGFR
Fig. 2. Activation of EGFR does not modify the binding of endoge-
nous CaM to the receptor. Solubilized whole cell extracts from
EGFR-T17 ¢broblasts (2 mg protein) and A431 tumor cells (3.1 mg
protein) from non-stimulated cultures (lanes 1 and 2) and cultures
stimulated with increasing concentrations (0.1, 1, 10, and 50 nM) of
EGF for 1 min (lanes 3^6) were subjected to immunoprecipitation
(IP) using an anti-EGFR antibody (K-EGFR). Mock immunopre-
cipitation experiments using a non-relevant mouse IgG fraction in-
stead of the anti-EGFR are also presented. The samples were pro-
cessed as in Fig. 1 and probed, respectively, with anti-
phosphotyrosine (K-P-Tyr), and anti-CaM (K-CaM) antibodies. The
upper part of the PVDF membrane was also stripped and reprobed
with the anti-EGFR (K-EGFR) antibody. Loading controls showing
the amount of IgG present in the samples as detected using the sec-
ondary anti-mouse IgG antibody (K-IgG) coupled to peroxidase are
also presented. The apparent molecular masses of the di¡erent
bands were as follows: phosphorylated and total EGFR 170 kDa,
CaM 21 kDa (because EGTA present), and IgG 55 kDa. Represen-
tative experiments of two performed in each cell line are presented.
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and an EGFR mutant in which the CaM-binding domain was
divided into two segments by the insertion of a non-relevant
highly acidic sequence of 23 amino acids between Arg647 and
His648 [21]. To perform these experiments, we used
N7xHERc and RI1 ¢broblasts expressing, respectively, the
wild type and the mutant EGFR. These cell lines express
comparable numbers of receptors per cell as suggested by
their similar phosphorylation levels.
Fig. 4A shows a time course of EGF-dependent tyrosine
phosphorylation of wild type EGFR from N7xHERc ¢bro-
blasts reaching a maximum at 1^2 min, followed by a rapid
partial dephosphorylation (t1=2W4 min), that reaches an ap-
parent steady state at 50% phosphorylation after 15 min, re-
maining roughly constant for up to 1 h (not shown). The
presence of W13 does not prevent the initial rapid EGFR
phosphorylation burst, but reaches a maximum only at half
the value of its control in the absence of CaM antagonist. As
Fig. 3. Cell-permeable CaM antagonists prevent full EGFR trans-
phosphorylation. A: N7xHERc ¢broblasts were treated with the in-
dicated concentrations of W12 (circles), W13 (triangles) or W7
(squares) for 15 min, and thereafter 10 nM EGF was added for
1 min. Transphosphorylation of EGFR was determined by Western
blot using an anti-phosphotyrosine antibody and quanti¢ed as de-
scribed in Section 2. The plot presents the averageVS.D. percent
phosphorylation level of EGFR from three independent experi-
ments. B: The plot presents the averageVS.D. percent inhibition of
EGFR transphosphorylation (n=3, vertical error bars) by 47 WM
W12 (circles), 43 WM W13 (triangles) or 40 WM W7 (squares) for 15
min, against the averageVS.D. inhibition constant (IC50) of these
compounds for CaM (n=2, horizontal error bars), as determined by
the manufacturer, inhibiting the activity of two distinct Ca2þ/CaM-
dependent enzymes, cyclic nucleotide phosphodiesterase and myosin
light chain kinase. The smallest horizontal error bars are hidden
within the symbols. Fig. 4. Disruption of the CaM-binding domain in an EGFR mutant
results in resistance to CaM antagonist treatment. N7xHERc ¢bro-
blasts (A) and RI1 ¢broblasts (B), expressing respectively the wild
type and mutant EGFR, were incubated in the absence (open sym-
bols) and presence (¢lled symbols) of 43 WM W13 for 15 min, and
thereafter 10 nM EGF was added for the indicated period of time.
Transphosphorylation of EGFR was determined by Western blot
using an anti-phosphotyrosine antibody and quanti¢ed as described
in Section 2. The plot presents the averageVS.D. percent phosphor-
ylation level of wild type (A) and mutant (B) EGFR from two (A)
or four (B) independent experiments. The smallest error bars are
hidden within the symbols.
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can be observed, the dephosphorylation of EGFR was greatly
reduced in the presence of W13.
When similar experiments were performed using RI1 ¢bro-
blasts, expressing the mutant EGFR with a disrupted CaM-
binding domain (see Fig. 4B), the phosphorylation/dephos-
phorylation kinetics of the receptor in the absence of W13
was almost identical to that of wild type EGFR (compare
open symbols in Fig. 4A,B). In contrast, the maximum level
of tyrosine phosphorylation of the mutant EGFR in W13-
treated cells reached nearly the same value as in the absence
of W13. We also noticed that the subsequent dephosphoryla-
tion of the mutant EGFR was greatly reduced in the presence
of W13 as compared with that in the absence of this drug,
similar to what was observed in wild type EGFR (compare
¢lled symbols in Fig. 4A,B).
4. Discussion
We have shown in this report that endogenous CaM binds
to EGFR as demonstrated by co-immunoprecipitation experi-
ments, suggesting that a CaM/EGFR complex is present in
living cells. However, the immune detection of di¡erent pro-
teins probed with diverse antibodies against distinct antigenic
determinants hardly can be compared to adequately quantify
the amount of two unrelated proteins present in a sample, as
this reaction greatly depends on non-comparable a⁄nities of
primary plus secondary antibodies for their respective targets.
Therefore, we could not determine in our experiments the
actual CaM/EGFR stoichiometry in the co-immunoprecipi-
tated complex. In view, however, of the large amount of pro-
tein needed for immunoprecipitation in order to detect a read-
able CaM signal, and because both EGFR-T17 and A431 cell
lines used in our experiments overexpress EGFR [19,20], we
suggest that this stoichiometry is probably low. If this were
the case, only a fraction of EGFR would be coupled to CaM
in living cells at a given time.
In general, comparing the immunoprecipitated EGFR from
non-treated and EGF-treated cells, we observed better EGF-
dependent stimulated phosphorylation of the receptor from
EGFR-T17 ¢broblasts than from A431 tumor cells. This could
be due to the fact that the latter cell line shows higher levels of
basal phosphorylation of EGFR than the former, perhaps be-
cause of autocrine/paracrine activation of the receptor by en-
dogenous EGFR ligand(s). The EGF-dependent phosphoryla-
tion of EGFR as measured in whole cell extracts from A431
tumor cells was, however, very high (not shown). This sug-
gests, therefore, that the antibody used to immunoprecipitate
EGFR could have relatively higher a⁄nity for the phosphor-
ylated receptor than for its non-phosphorylated form.
Although EGFR activation generates a transient increase in
the [Ca2þ]cyt [1], our results show that the extent of binding of
endogenous CaM to EGFR is independent of its tyrosine
phosphorylation status. It is important to have in mind that
CaM could interact with a distinct yet unknown pool of
EGFR molecules, as low-a⁄nity and high-a⁄nity EGFR spe-
cies are known to be present in the cell. The location of func-
tional EGFR molecules in several subcellular compartments
including the plasma membrane [24], endosomes [25], and
even the nucleus [26,27], and nucleoli [27] has been reported.
This o¡ers the possibility that CaM could interact with the
receptor in specialized subcellular regions performing speci¢c
tasks.
The precise role of CaM on the functional cycle of EGFR
in living cells is yet unknown. However, the implication of this
Ca2þ sensor in the modulation of the receptor tyrosine kinase
activity at the plasma membrane [12,13], during its internal-
ization [14], intracellular sorting and tra⁄cking [18], and even
during its nuclear translocation [15,17,27] has been demon-
strated and/or suggested. In the latter case, this is supported
by the fact that the reported CaM-binding domain and the
nuclear localization sequence of EGFR have overlapping se-
quences [14,17,26,27]. Our results demonstrate that CaM in-
deed has a regulatory role on EGFR in living cells, as using
cell-permeable CaM antagonists we observed a depletion of
EGF-activatable receptors in the cells, and W7 has been
shown to inhibit EGF-induced, but not EGF-independent,
proliferation of a human hepatoma cell line [28]. Because
W13 promotes the sequestration of EGFR at endosomes
[18], the amount of EGF-responsive receptors at the cell sur-
face would be expected to decrease upon treatment with this
CaM antagonist, perhaps explaining in this manner the de-
creased tyrosine phosphorylation of EGFR observed in our
experiments.
Although calcineurin has been shown to dephosphorylate
phosphotyrosine residues of EGFR in vitro [29,30], little is
known about the implication of this CaM-dependent phos-
phoserine/threonine phosphatase on the dephosphorylation
of EGFR in intact cells. Our results show, however, that in-
hibition of endogenous CaM with W13 relents EGFR dephos-
phorylation, suggesting that calcineurin could directly or in-
directly be involved in the process.
The cytosolic juxtamembrane region of EGFR has been
implicated in the control of multiple receptor functions [15],
including those mediated by the binding of CaM to this re-
gion, more precisely between residues Arg645 and Gln660
[14,15,17]. Although the identi¢cation of this CaM-binding
domain in EGFR represented a signi¢cant advance in our
understanding of the functionality of this receptor, the in-
volvement of this site in the binding of CaM in living cells
has not been previously determined. Our results now show for
the ¢rst time that disruption of the positively charged amphi-
philic helical structure of the CaM-binding domain of EGFR
in the insertional mutant used renders the receptor mostly
insensitive to W13 action. Hence, the receptor remains nearly
fully activatable by EGF in the presence of this CaM antag-
onist, although its subsequent dephosphorylation is signi¢-
cantly blocked. The reason for this manifold behavior is not
yet fully understood, as several CaM-dependent systems with
distinct a⁄nities for CaM are notoriously operative on
EGFR. Thus, phosphorylation of the receptor by CaMK-II,
which is a high-a⁄nity system [10,11], and direct binding of
CaM to EGFR, which is a low-a⁄nity system [12,14,16], are
at work. However, one possibility that could explain these
results is that a signi¢cant, but yet partial, decrease of active
cellular CaM subjects the wild type EGFR prone to endosome
sequestration as proposed [18]. Therefore, the high-a⁄nity
CaMK-II systems could still be in operation, while the ab-
sence of a functional CaM-binding domain in the mutant
EGFR retains this receptor at the cell surface, and therefore
remains able to undergo EGF-dependent activation. This is in
agreement with our suggestion that binding of CaM to EGFR
may be required for its internalization [14]. We have also
observed in cells overexpressing EGFR, such as EGFR-T17
and A431, that the inhibitory action of W13 on EGF-depen-
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dent receptor phosphorylation was only observed in the pres-
ence of the Ca2þ ionophore A23187 (Ruano and Villalobo,
unpublished results). This suggests that the increase in
[Ca2þ]cyt generated upon EGF stimulation in the absence of
the ionophore was low enough in these cell lines.
Because disparate signals converge on EGFR to dictate
their function and fate, and the CaM-dependent mechanisms
directly or indirectly acting on the receptor appear to be mul-
tiple, the study of CaM-regulated EGFR functions in living
cells is highly complex and laborious to analyze. Therefore,
additional work should be performed to determine as a lead-
ing priority the subcellular location of EGFR species able to
interact with CaM. The use of various technologies to mon-
itor real-time protein^protein interactions in living cells could
help in this task.
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